secwatch.observer — SEC 8-K summary
======================================

Issuer:     MoonLake Immunotherapeutics (MLTX)
CIK:        0001821586
Form:       8-K
Filed at:   2026-06-22T11:00:32+00:00
Accession:  0001213900-26-070362
Event type: other_material
Sentiment:  positive
Materiality: 0.85
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

MoonLake Phase 3 VELA Week 52: 67% HiSCR75, 33% HiSCR100; BLA submission end-Sept 2026
--------------------------------------------------------------------------------

- Across VELA-1/2, 67.2% of SLK-treated patients achieved HiSCR75, 33.1% HiSCR100 at Week 52 (n=396).
- 26.0% achieved IHS4-100 remission; HiSQOL improved by mean -15.0 points from baseline.
- 46.5% of patients had marked pain reduction (≥3-point drop in worst skin pain NRS).
- VELA-TEEN interim: ~68% HiSCR75, ~45% HiSCR100 at Week 24 in adolescents (n=22).
- BLA submission for SLK in HS expected end of September 2026; PDUFA date by late Nov 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1821586/000121390026070362/0001213900-26-070362-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1821586/000121390026070362/ea0295399-8k_moonlake.htm
  HTML page:      https://secwatch.observer/filing/0001213900-26-070362

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer